Provided by Tiger Trade Technology Pte. Ltd.

WisdomTree BioRevolution Fund

23.68
+0.04760.20%
Post-market: 23.680.00000.00%16:10 EDT
Volume:2K
Turnover:58.12K
Market Cap:4.74M
PE:- -
High:23.71
Open:23.71
Low:23.48
Close:23.63
52wk High:24.29
52wk Low:15.67
Shares:200.00K
Float Shares:200.00K
Volume Ratio:1.89
T/O Rate:1.23%
Dividend:0.77
Dividend Rate:3.26%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT

Reuters
·
Oct 01

Sector Update: Healthcare

MT Newswires Live
·
Oct 01

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
Oct 01

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Option traders moderately bearish in Moderna with shares down 6.7%

TIPRANKS
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Moderna Inc Stock (MRNA) Opened Down by 6.27% on Sep 30: Key Drivers Unveiled

TradingKey
·
Sep 30

Moderna Names Juan Andres Chief Operating Officer

Dow Jones
·
Sep 30

Moderna Shares Down 7.5% After Citigroup Cuts to Sell from Neutral

THOMSON REUTERS
·
Sep 30

Moderna, Concentrix, Boeing, HPE, Robinhood, Cal-Maine, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30